Bristol-Myers Squibb Company (NYSE:BMY) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).
FierceBiotech4h
Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...
ENDPOINTS NEWS18h
Bris­tol My­ers prunes pipeline amid new round of cost cuts
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...
Zacks.com on MSN3d
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6 ...